Palisade Bio, Inc. (PALI) Financials

PALI Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 127.3 million 5.6 million
March 31, 2026 133.3 million 6.0 million
Dec. 31, 2025 134.3 million 5.0 million
Sept. 30, 2025 7.0 million 3.8 million

PALI Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -7.6 million 4.8 million
March 31, 2026 -3.9 million 4.3 million
Dec. 31, 2025 -3.1 million 3.7 million
Sept. 30, 2025 -3.6 million 90000

PALI Net Income

No data available :(

PALI Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 125.2 million - -
March 31, 2026 132.6 million - -
Dec. 31, 2025 133.4 million - -
Sept. 30, 2025 5.2 million - -

PALI Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 211.4 million
March 31, 2026 209.7 million
Dec. 31, 2025 55.7 million
Sept. 30, 2025 7.5 million

PALI Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 7.4 million 4.8 million -
March 31, 2026 - 6.4 million 4.4 million -
Dec. 31, 2025 - 6.2 million 3.8 million -
Sept. 30, 2025 - 1.4 million 1.5 million -

PALI Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 500000 -
March 31, 2026 - -
Dec. 31, 2025 - -
Sept. 30, 2025 - -

PALI

Price: $1.41

52 week price:
1.32
2.86

Earnings Per Share: 0.65 USD

P/E Ratio: 3.29

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 369800

Market Capitalization: 250.0 million

Links: